Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Slow-Go Strategy for High Risk AL Amyloidosis: Isatuximab for Upfront Therapy

NCT04754945 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT04754945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04754945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Slow-Go Strategy for High Risk AL Amyloidosis: Isatuximab for Upfront Therapy
Lead sponsor
Emory University
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 28, 2021
Completion date
July 24, 2028
Enrollment
11 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

al amyloidosis